Compare DexCom, Inc. (DXCM) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Goldman Sachs Group Inc — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while Goldman Sachs Group Inc trades at $1,118.97 (market cap $339.87B). The key difference: Goldman Sachs Group Inc is far larger — about 12.1× DexCom, Inc.'s market cap, and Goldman Sachs Group Inc pays a 1.56% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | GS | |
|---|---|---|
Market Cap | $28.06B | $339.87B |
Sector | Health | Financials |
52-Week High | $89.53 | $1.15K |
52-Week Low | $54.84 | $700.41 |
Enterprise Value | $27.03B | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Goldman Sachs (GS) trades at $1,140, up 9.0% over 24 hours, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $20.98 versus $14.47, and revenue growth from $58.28B in 2025 to $60.4B projected for 2026. Recent news highlights Goldman's role in leading high-profile IPOs including Anthropic, signaling strong investment banking pipeline strength.
Outlook remains positive with analyst consensus price target of $1,140K and 40% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include volatile cash flow patterns and high leverage, while institutional sentiment supports continued growth from M&A activity and AI-driven market opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
